Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
AST-008 (TLR9 agonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):